Tag: <span>Sarep­ta</span>

Home / Sarep­ta
Post

Why not? Sarepta’s third Duchenne MD drug sails to accelerated approval

Amber Tong Senior Editor Sarep­ta may be run­ning in­to some trou­ble with its next-gen gene ther­a­py ap­proach to Duchenne mus­cu­lar dy­s­tro­phy. But when it comes to an­ti­sense oligonu­cleotides, the well-trod­den reg­u­la­to­ry path is still lead­ing straight to an ac­cel­er­at­ed ap­proval for casimersen, now chris­tened Amondys 45. We just have to wait un­til 2024 to find...